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Abstract
Background: Chromogranin-A (CgA) is a secretory protein processed into peptides that regulate angiogenesis and
vascular cells activation, migration and proliferation. These processes may influence arterial inflammation and
remodelling in Takayasu arteritis (TA).
Methods: Plasma levels of full-length CgA (CgA439), CgA fragments lacking the C-terminal region (CgA-FRs) and the
N-terminal fragment, CgA1–76 (vasostatin-1, VS-1) were analysed in 42 patients with TA and 20 healthy age-matched
controls. Vascular remodelling was longitudinally assessed by imaging. CgA peptides were related to markers of
systemic and local inflammation, disease activity and vascular remodelling.
Results: Levels of CgA-FRs and VS-1 were increased in TA. Treatment with proton-pump inhibitors (PPIs) and
arterial hypertension partially accounted for CgA levels and high inter-patient variability. CgA439, CgA-FRs and VS-1
levels did not reflect disease activity or extent. Markers of systemic or local inflammation correlated with higher
CgA-FRs and VS-1 in normotensive patients and with higher CgA439 in hypertensive patients. Treatment with non-
biologic anti-rheumatic agents was associated with increased CgA-FRs and a distinctive regulation of CgA
processing. Reduced blood levels of anti-angiogenic CgA peptides were associated with vascular remodelling in the
groups of patients on PPIs and with arterial hypertension.
Conclusions: The plasma levels of CgA fragments are markedly increased in TA as a consequence of disease- and
therapy-related variables. Anti-angiogenic forms of CgA may limit vascular remodelling. Given the effect of the
various CgA peptides, it is advisable to limit the therapeutic prescriptions that might influence CgA-derived peptide
levels to clearly agreed medical indications until further data become available.
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Background
Takayasu arteritis (TA) is a rare idiopathic chronic-
relapsing large vessel vasculitis, usually affecting young
women and associated with considerable morbidity and
mortality [1–4]. Typical arterial lesions affect the aorta
and its major branches, with wall thickening and pos-
sible remodelling resulting either in steno-occlusion or
in dilatation up to aneurysm formation [1, 4, 5]. Limiting
the progression of vascular lesions is an important thera-
peutic target in TA [6] as vascular complications have a
prognostic impact [7]. However, we lack reliable bio-
markers to assess disease activity and vascular progres-
sion. Despite TA being an inflammatory disease, the
relationship between systemic inflammation and vascular
progression is loose, as about 60 % of patients believed
to be in remission and without evidence of systemic
inflammation develop new arterial lesions on serial
angiographic studies [5]. Local inflammation and/or
pauci-inflammatory vascular remodelling might be even
relevant in the evolution of lesions [8–11] in the context
of a long-lasting injury caused by immune response
against vascular antigens [11]. Indeed, intimal hyperpla-
sia, which is a stereotyped remodelling response to many
vascular injuries, is a typical finding in TA lesions and
contributes to wall thickening. Locally generated or re-
leased growth factors such as fibroblast growth factor
and platelet-derived growth factor might contribute to
intimal hyperplasia. Vasa vasorum neoangiogenesis and
migration/proliferation of medial vascular smooth muscle
cells (VSMCs) are associated with intimal hyperplasia and
arterial remodelling in giant cell arteritis (GCA), a large
vessel vasculitis cognate of TA [11, 12].
Chromogranin-A (CgA) is a protein stored in
secretory granules of many neuroendocrine cells, neu-
rons, granulocytes and cardiomyocytes [13, 14]. CgA has
a crucial intracellular role in secretory granule biogenesis
and calcium homeostasis [14]. Tissue-specific and
context-specific proteolytic cleavage of CgA yields poly-
peptides with paracrine and endocrine activity (hence re-
ferred as the CgA system) [14, 15]. At least four CgA
polypeptides containing the N-term region have been
detected in the blood of healthy subjects, including full-
length CgA protein (or CgA439), large fragments cleaved
after residue 436, various polypeptides spanning from
the N-terminus to the central region but lacking the C-
terminal region (CgA-FRs) and the N-terminal peptide
CgA1–76, alias vasostatin-1 (VS-1) [15]. CgA439, CgA-
FRs and VS-1 differentially modulate angiogenesis [15].
It has been recently shown that CgA contains a func-
tional anti-angiogenic site in the C-terminal region 410–
439 [15]. Thus fragments lacking the C-terminal regions
(CgA-FRs) are devoid of anti-angiogenic activity. In
addition, CgA contains a latent anti-angiogenic site in
the N-terminal region 1–76 and a pro-angiogenic site in
the region 352–372, which can be activated by the proteo-
lytic cleavage of Q76–K77 and R373–R374, respectively
[15]. Accordingly, CgA439 and VS-1 inhibit angiogenesis
in various angiogenic assays, whereas CgA1–373 (one of
the CgA-FRs) and the CgA-FRs produced by thrombin di-
gestion of CgA can induce the secretion of fibroblast
growth factor-2 (FGF2) from endothelial cells and stimu-
late angiogenesis [15, 16]. The CgA-dependent regulation
of the angiogenic switch has been demonstrated in the
bone marrow of patients with multiple myeloma and ex-
perimental murine models of the disease further strength-
ening the contention that the balance between pro- and
anti-angiogenic CgA-derived peptides has important phys-
iopathological consequences [17].
CgA-related polypeptides can also influences fibroblast
adhesion, endothelial and VSMC proliferation and mi-
gration, endothelial response to inflammatory stimuli,
cardiac function and vascular tone [14–16, 18–23]. Fur-
thermore, CgA439 accelerates wound healing in mice in
a process dependent on the integrin αvβ6 [24]. Based on
these evidences, it has been hypothesized that local and
systemic changes in the concentrations of CgA and its
fragments may contribute to the homeostatic vascular
regulation in normal conditions as well as of vascular in-
flammation and remodelling in response to injury.
Increased blood levels of CgA have been shown in nu-
merous inflammatory and non-inflammatory conditions,
including neuroendocrine tumours, renal failure, arterial
hypertension, chronic heart failure and rheumatoid
arthritis [18, 25]. Concurrent therapy can also influence
CgA levels: for example, proton-pump inhibitors (PPIs,
frequently used in patients on steroid therapy) increase
the circulating levels of CgA by inducing hyperplasia of
the gastric entherochromaffin cells. CgA is particularly
elevated in patients with refractory GCA and might rep-
resent a marker of smouldering disease [26].
Here, we assessed the plasmatic levels of CgA439,
CgA-FRs and VS-1 and the relative proportions (ratios
of each peptide to total CgA, CgAtot) in TA. To under-
stand the link with arterial remodelling, we verified
whether their concentrations correlate with inflamma-
tory and non-inflammatory features of TA.
Methods
Study sample
Fifty-one patients fulfilling the American College of
Rheumatology (ACR) criteria for TA [27] were evaluated
in 2013 at the San Raffaele Scientific Institute in Milan.
All patients were extensively evaluated to exclude TA
mimics, as previously described [10]. We performed a
cross-sectional analysis of disease biomarkers between
April and August 2013, excluding nine patients that did
not attend a visit in that period or had moderate to se-
vere renal or heart failure, and carried out a longitudinal
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evaluation of arterial involvement as assessed by serial
radiological imaging follow-up (see below). The final
sample consisted of 42 consecutive patients with a me-
dian age of 46 years (range 23 to 66 years). Twenty age-
matched women served as healthy controls (HCs). All
subjects gave written informed consent for participation
in the study and the Institutional Review Board of the
San Raffaele University Hospital (Comitato Etico del-
l’Ospedale San Raffaele, Milano, Italy) approved the
study protocol (protocol “Autoimmuno-mol”, PI Angelo
Manfredi). This study was conducted in accordance with
the Declaration of Helsinki.
Clinical assessment and laboratory biomarkers
Systemic activity of TA was evaluated according to
National Institutes of Health (NIH) criteria [5]. Arterial
hypertension was defined in accordance with inter-
national guidelines. Cardiac involvement was defined as
significant aortic regurgitation or presence of systolic or
diastolic dysfunction. Three inflammatory reactants were
evaluated: erythrocyte sedimentation rate (ESR), and
concentration of C-reactive protein (CRP) and of
pentraxin-3 (PTX3). ESR was assessed by the Westergren
method, CRP by a latex-enhanced immuno-turbidimetric
assay (ADVIA Chemistry System, Bayer AG, Leverkusen
Germany), and plasma PTX3 by ELISAs as previously de-
scribed [10]. Four sandwich ELISAs were used to detect
CgA-derived polypeptides (Additional file 1: Figure S1)
[15]: (1) 439 ELISA, that specifically detects CgA439; (2)
436/439 ELISA, that detects the peptides with the N-
terminal domain and the C-terminal region, with or
without the 436–439 residues; (3) 436/439 + FRs-ELISA,
that detects peptides with the N-terminal domain and the
central region; (4) 76 ELISA, that detects VS-1. CgAtot
was computed summing the results of 436/439 + FRs-
ELISA and 76 ELISA, thus including all the CgA-derived
polypeptides containing the N-terminal region. Given that
both CgA439 and VS-1 have anti-angiogenic properties,
we pooled these two polypeptides by summing the ranks
of the respective peptides in our sample. The levels of
CgA-FRs were computed subtracting the results of
436/439 + FRs ELISA and 436/439 ELISA. To study
the regulation of CgA processing, we evaluated the
ratios of CgA439/CgAtot, CgA-FRs/CgAtot and VS-1/
CgAtot. There were no samples missing for CRP,
PTX3 and CgA or derived peptides assessment. Three
samples were missing for ESR. Samples were analysed
in a random order and in a blinded manner.
Imaging assessment
All patients were regularly monitored with magnetic res-
onance angiography (MRA) and vascular ultrasonog-
raphy (US). Two patients had contraindications to MRA
and underwent computed tomography angiography
(CTA). MRA was performed with a 1.5-T magnetic
resonance whole body scanner (Achieva Nova Master;
Philips Medical Systems, Best, The Netherlands) with
phased-array head and neck or phased-array thoracic
dedicated coils. Morphologic sequences [proton-density
weighted (PD) black blood turbo spin echo (TSE): field
of view (FOV) 260 × 152; acquisition (Acq) matrix =
260 × 264; reconstruction (Recon) matrix = 528; Acq
voxel MPS = 1.00/0.95/6.00; Recon voxel MPS = 0.49/
0.49/600; echo time/repetition time (TE/TR) = 20/2
beats; electrocardiogram (ECG) triggered; in expiratory
breath hold of approximately 10 sec] were performed to
evaluate vessel wall thickening. First-pass MRA dynamic
sequences targeted on thoraco-abdominal aorta and
supra-aortic trunks (FOV 450 × 390; Acq matrix = 352 ×
200; Recon matrix = 670; Acq voxel = 1.28/1.90/3.00; Rec
voxel = 0.67/0.67/1.5; slice thickness = 1.5 mm; TR/TE/α =
4.6/1.35/40; acquisition time = 21 sec) were performed
during contrast media infusion (Gadovist®: 1 nmol/ml
Bayer Pharma, Berlin, Germany). High-resolution (HR) se-
quences were performed before and after contrast admin-
istration [coronal HR three-dimensional (3D) fast field
echo (FFE): FOV 360 × 276; Acq matrix = 684 × 521; Rec
matrix 880; slice thickness = 0.8 mm; TR/TE/flip angle
(FA) = 6.3/2.1/20; acquisition time = 3:28 min]. These se-
quences allow the evaluation of vessel wall thickness up to
1 mm. CTA was performed with a Brilliance CT 64-
channel scanner (Philips Medical Systems, Best, The
Netherlands) with administration of 130 ml of Ultravist
370 (Bayer Healthcare LCC, Leverkusen, Germany) at a
flow rate of 5 ml/sec. US was performed with iU22 Matrix
Ultrasound system (Philips Medical Systems). US and
CTA evaluations assessed carotid, subclavian, abdominal
and femoral districts, while MRA was focused on
thoraco-abdominal or cervico-thoracic regions accord-
ing to disease involvement. Lesions were evaluated by
two radiologists with an expertise in cardio-vascular
imaging, blinded to the clinical status of patients. Vari-
ables evaluated for each lesion at MRA and CTA in-
cluded lesion width, length, residual lumen and
contrast enhancement. Since gadofosveset trisodium
was retired, the presence or absence of vessel wall en-
hancement was scored by two radiologist experts in
cardio-vascular imaging, blinded to the clinical status
of patients. Enhancement data were available for 30 pa-
tients. At US, lesions width, residual lumen, peak sys-
tolic blood flow velocity and the presence of the halo
sign were assessed. Imaging follow-up occurred yearly
or, in case of relapses, until disease enters the tardive
phase, clinical and morphological stability for at least
3–5 years.
Progression in arterial involvement was defined as ap-
pearance of novel lesions or as increase in width and/or
length and/or percentage of luminal stenosis of established
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vasculitic lesions at follow-up. Two patients were eva-
luated with imaging only at a single time point, and pro-
gression over time could not be assessed. Progressive
enlargement of ectasias/aneurysms may be related to
biomechanical factors independent of disease activity.
Therefore, it has not been included in the definition
of progression of arterial involvement. Similarly, pro-
gression due to concurrent atherosclerosis was not
taken into account. Confounder atherosclerotic lesions
were identified and excluded on the basis of typical
sites (arterial branches), eccentric appearance of the
lesions, short and focal lesions, inhomogeneous con-
tent and irregular luminal border on US, the presence
of parietal calcifications on the luminal side of the le-
sion and the absence of halo signs or adventitial
thickenings on US.
Statistical analysis
We expressed scalar variables as median values and
ranges. Mann-Whitney U test was used to compare bio-
markers between patients with TA and controls, or be-
tween various subgroups of patients with TA stratified
according to the presence or the absence of therapy with
PPIs, steroids and immunosuppressive agents, arterial
hypertension, wall enhancement, vascular progression
and active disease. Multivariate analysis with multi-
factor analysis of variance (ANOVA) was performed to
verify the relationship between stratifying variables and
plasma levels of CgA fragments. Plasma levels of
CgA439, CgA-FRs and VS-1, their ratio to CgAtot and
the anti-angiogenic CgA potential were used as depend-
ant variables of the analysis. Five candidate factors were
considered in the model on the basis of their clinical
relevance and of their potential involvement: therapy
with PPIs, presence of arterial hypertension, vascular
progression, therapy with prednisone and therapy with
immunosuppressive agents. Considering the sample size,
we set the optimal number of factors in the model at
four to avoid over-parameterization and loss of statistical
power. Given the evidence of the impact of therapy with
PPIs on plasma CgA levels [28] and the association be-
tween treatment with PPI and with steroids in our sam-
ple (p < 0.001), the latter was excluded from the final
model, resulting in a four-way ANOVA. Kruskal-Wallis
test was used to compare values of biomarkers within
various classes of arterial involvement [29]. Spearman
rank correlation coefficient was calculated for the correl-
ation analyses. Associations were evaluated with χ2 test
and Fisher exact test.
A two-tailed p value less than 0.05 was considered to
represent statistically significant differences, and p values
less than 0.10 were shown in the tables. Statistical ana-
lysis was performed with IBM SPSS Statistics, version 20
(IBM Corp., Armonk, NY, USA).
Results
Patient characteristics
Table 1 summarizes the demographic, clinical and la-
boratory characteristics of patients with TA (42 subjects,
39 women and three men) and of age-matched HCs (20
women). The median age at TA onset was 30 years
(range 17–56 years). Thirty-seven (88 %) TA patients
had a widespread diffuse arterial involvement (angio-
graphic class II or V). Sixteen patients (38 %) had arter-
ial aneurysms. Thirty-eight patients (90 %) were on
treatment: 30 received steroids, 30 immunosuppressive
agents (12 azathioprine, 11 methotrexate, four mofetil
mycophenolate, two sirolimus, one cyclophosphamide),
16 tumour necrosis factor (TNF) blockers, two toci-
lizumab and one rituximab. Thirty patients were on
treatment with proton-pump inhibitors (PPIs). Twelve
patients (29 %) fulfilled the NIH criteria for active TA.
Arterial wall enhancement was detectable in 16 % (5/30)
and vascular progression in 22 % (9/40) of the patients.
Twenty-two (52 %) patients had arterial hypertension.
CRP and PTX3 concentrations were higher in pa-
tients with TA (2.6 mg/l, 0.1–40 mg/l and 5.5 ng/ml,
1.3–55 ng/ml, respectively) than in HCs (0.6 mg/l,
0.3–9.0 mg/l, p = 0.017 and 3.9 ng/ml, 1.4–6.5 ng/ml,
p = 0.009 respectively).
CgA levels in TA
The CgA system encompasses a family of variably proc-
essed polypeptides. We estimated total CgA (CgAtot)
concentration by assessing all the polypeptides contain-
ing the N-terminal region, i.e. by summing the results of
436/439 + FRs ELISA and 76 ELISA [15]. CgAtot was
higher in patients with TA than in HCs (2.36 nM, range
0.45 to 7.85 nM vs 0.98 nM, range 0.47 to 1.72 nM, p =
0.001; Fig. 1a and Table 1). Similarly, TA patients had
higher plasmatic CgA-FRs and VS-1 than HCs (p = 0.001
and 0.020, respectively; Fig. 1b and Table 1). The inter-
subject variability of the levels of CgA-derived polypep-
tides was high, especially in the TA group and for
CgA439 levels (Fig. 1a-b and Table 1), which had the
highest coefficient of variation (not shown).
We evaluated disease-related and therapy-related vari-
ables. TA patients on PPIs (30/40, 75 %) had significantly
more active disease (p = 0.009) and were more frequently
treated with steroids than patients without PPIs (p <
0.001, Table 2). Levels of CgAtot were higher in the
group on PPIs. Specifically, patients on PPIs had higher
concentrations of CgA-FRs and VS-1 (Fig. 1c and
Table 2). High inter-patient variability in the levels of
CgAtot, CgA439, CgA-FRs and VS-1 persisted after strati-
fication for PPI treatment (Fig. 1c and Table 2). CgA439/
CgAtot, CgA-FRs/CgAtot and VS-1/CgAtot ratios were
similar in patients whether or not on PPI therapy (Fig. 1d
and Table 2). These data suggest that PPIs apparently do
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Table 1 Characteristics of the TA patients and HCs
HCs TA (N = 42) p value
Qualitative variables
Sex (F:M) 20:0 39:3 n.s.
Class of arterial involvement: N.E.
1
2A
2B
3
4
5
-
-
-
-
-
-
4 (10 %)
4 (10 %)
3 (7 %)
1 (2 %)
0
30 (71 %)
-
-
-
-
-
-
Coronary involvement N.E. 6 (14 %) -
Pulmonary artery involvement N.E. 13 (31 %) -
Aneurysms 0 16 (38 %) -
Steroids 0 30 (71 %) -
Immunosuppressive therapy:
Azathioprine
Methotrexate
Mycophenolate
Sirolimus
Cyclophosphamide
0
-
-
-
-
-
30 (71 %)
12 (29 %)
11 (26 %)
4 (10 %)
2 (5 %)
1 (2 %)
-
-
-
-
-
-
Biologic therapy:
TNF blockers
Tocilizumab
Rituximab
0
-
-
-
19 (45 %)
16 (38 %)
2 (5 %)
1 (2 %)
-
-
-
-
Active disease (NIH criteria) N.E. 12 (29 %) -
Anticoagulants 0 7 (17 %) -
Arterial hypertension 0 22 (52 %) -
Cardiac involvement N.E. 12 (29 %) -
Vascular enhancement (N = 30) N.E. 5 (16 %) -
Vascular progression (N = 40) N.E. 9 (22 %) -
Scalar variables (median, range)
Age at disease onset (years) N.E. 30 (17–56) -
Disease duration (years) N.E. 10 (0-34) -
Creatinine (mg/dl) N.A. 0.70 (0.44–1.60) -
PDN dose (mg/day; N = 30) 0 5 (3–35) -
N vessels N.E. 4 (1–7) -
ESR (mm/h) N.A. 15 (1–78) -
Serum CRP (mg/l) 0.6 (0.3–9.0) 2.6 (0.03–40) 0.017
Plasma PTX3 (ng/ml) 3.9 (1.4–6.5) 5.5 (1.3–55) 0.009
CgAtot (nM) 0.98 (0.47–1.72) 2.36 (0.45–7.85) 0.001
CgA439 (nM) 0.04 (0–0.07) 0.05 (0-0–.78) n.s.
CgA-FRs (nM) 0.64 (0.22–1.17) 1.63 (0.22–6.68) 0.001
VS-1 (nM) 0.10 (0.07–0.50) 0.20 (0.02–1.15) 0.020
CgA439/CgAtot 5 % (0–17 %) 1 % (0–24 %) n.s.
CgA-FRs/CgAtot 67 % (46–88 %) 66 % (47–94 %) n.s.
VS-1/CgAtot 13 % (7–29 %) 11 % (1–27 %) n.s.
Quantitative and qualitative variables related to TA were evaluated in TA patients and healthy controls (HCs). N vessels refers to the number of vessels involved
by the disease (see “Methods”)
TA Takayasu arteritis, n.s. not significant, TNF tumour necrosis factor, N.E. not evaluable, N.A. not available, PDN prednisone, ESR erythrocyte sedimentation rate,
CRP C-reactive protein, PTX3 pentraxin-3, CgAtot total chromogranin-A, CgA439 full-length CgA (residues 1–439), CgA-FRs fragments of CgA spanning from the
N-terminus to the central region but lacking the C-terminal region, VS-1 vasostatin-1
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Fig. 1 (See legend on next page.)
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not influence CgA processing and only partially account
for the high inter-patient variability observed.
Arterial hypertension is associated with higher CgA-FRs
and VS-1 in TA
Twenty-two patients had arterial hypertension. Hyper-
tensive patients were more often treated with non-
biologic immunosuppressive agents and showed a trend
towards higher creatinine levels (Table 2). Levels of
CgA-FRs and VS-1 were higher in hypertensive TA pa-
tients (p = 0.030 and 0.024, respectively, Fig. 1e and
Table 2). To take into account the possible confounding
effect of PPIs, we repeated the analysis in TA patients
on PPIs, observing significantly higher concentrations of
CgA-FRs (p = 0.035) and a trend toward increased VS-1
(p = 0.087, Fig. 1f and Additional file 2: Table S1). Similar
CgA439/CgAtot, CgA-FRs/CgAtot and VS-1/CgAtot were
observed in the presence or the absence of arterial hyper-
tension in the whole sample (Table 2) and after stratifica-
tion for PPI therapy (Additional file 2: Table S1).
CgA439, CgA-FRs and VS-1 differentially reflect systemic
and local inflammation in normotensive and hypertensive
TA patients
Plasma concentration of CgA-derived polypeptides did
not reflect systemic inflammation (as measured by ESR
and CRP) or local inflammation (as assessed by PTX3
levels [9] and/or by the presence of arterial wall en-
hancement at imaging). In particular, ESR and PTX3 did
not correlate with the levels of CgA439, CgA-FRs, VS-1,
CgA439/CgAtot, CgA-FRs/CgAtot and VS-1/CgAtot in TA
patients, even after stratification for PPI therapy
(Table 3). CRP concentrations correlated with CgA-FRs
but the correlation was lost after stratification for PPI
treatment. Levels of CgA439, CgA-FRs and VS-1 (Fig. 2a-b),
and their ratios to CgAtot were similar in patients with or
without arterial wall enhancement at imaging.
In normotensive patients, VS-1 levels correlated posi-
tively with the concentration of CRP (Spearman coeffi-
cient 0.576, p = 0.008), and VS-1/CgAtot correlated with
ESR and PTX3 values (Spearman coefficient 0.684, p =
0.003 and 0.480, p = 0.032, respectively). CgA-FRs posi-
tively correlated with ESR (Spearman coefficient 0.570,
p = 0.021; Table 3 and Additional file 3: Figure S2A-D).
In hypertensive patients, CgA439 and CgA439/CgAtot
positively correlated with ESR (Spearman coefficient
0.517, p = 0.020 and 0.536, p = 0.015, respectively), while
VS-1/CgAtot negatively correlated with ESR and CRP
(Spearman coefficient -0.561, p = 0.010 and -0.455, p =
0.033, respectively; Table 3 and Additional file 3:
Figure S2E-H). These data suggest that arterial hyper-
tension influences the link between the CgA system
and inflammation in TA.
CgA439, CgA-FRs and VS-1 levels do not reflect disease
activity, extent or progression
Similar concentrations of CgA439, CgA-FRs and VS-1
(Fig. 2 and Table 4) and CgA439/CgAtot, CgA-FRs/CgAtot
and VS-1/CgAtot (data not shown) were observed in pa-
tients with active versus inactive disease, defined based
on NIH criteria [5]. Moreover, levels of CgA439, CgA-
FRs and VS-1 and their ratios to CgAtot did not correlate
with the number of arterial lesions as a measure of dis-
ease extent (Table 3). Concentrations of CgA439, CgA-
FRs and VS-1 were similar in patients regardless of the
presence of vascular progression, defined as appearance
of novel lesions or of increased thickness and/or length
and/or percentage of luminal stenosis of established
vasculitic lesions as assessed by imaging follow-up. We
assessed the anti-angiogenic CgA potential by summing
the ranks within the TA sample of CgA439 and VS-1
[17]. We found that the anti-angiogenic CgA potential
was unrelated to disease activity, to the number of in-
volved vessels and to vascular progression. The group of
patients on PPIs comprises eight out of the nine patients
undergoing vascular progression. Vascular progression
in patients on PPIs was associated with a significantly re-
duced anti-angiogenic CgA potential (p = 0.01, Table 4).
The anti-angiogenic CgA potential was as well signifi-
cantly reduced in hypertensive TA patients undergoing
progression of the vascular damage (p = 0.05, Table 4).
Immune-modulating agents modulate CgA levels and
fragmentation in TA
Patients on prednisone had increased CgA-FRs (Additional
file 4: Table S3). The difference was lost after stratification
for PPIs (Additional file 4: Table S3) or for arterial
hypertension (data not shown). Patients on conventional
(See figure on previous page.)
Fig. 1 Levels of CgA-derived polypeptides in patients with TA. a Plasma concentrations of total CgA, obtained summing the concentration of the
full-length molecule with that of the various CgA fragments in patients with TA and HCs (see “Methods”). ***: significantly different from HCs,
p≤ 0.001. b Plasma concentrations of CgA439, CgA-FRs and VS-1 in patients with TA and HCs.
*** and *: significantly different from HCs, p≤ 0.001
and p≤ 0.05 respectively. c Plasma concentrations of CgA439, CgA-FRs and VS-1 in TA patients with or without PPIs.
***: significantly different from
patients without PPIs, p≤ 0.001. d Ratios of CgA439, CgA-FRs and VS-1 to CgAtot in TA patients with or without PPIs. e-f Plasma concentrations of
CgA439, CgA-FRs and VS-1 in normotensive versus hypertensive patients either in the whole group of TA patients (panel e) and in those on PPIs
(panel f). *: significantly different from normotensive patients. AH arterial hypertension, CgA439 full-length chromogranin-A (residues 1–439),
CgA-FRs, fragments of CgA spanning from the N-terminus to the central region but lacking the C-terminal region, CgAtot total CgA, HC healthy
controls, PPI proton-pump inhibitors, TA Takayasu arteritis, VS-1 vasostatin-1
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Table 2 Characteristics of the TA patients stratified for therapy with PPIs and for the presence of arterial hypertension
Therapy with PPIs Arterial hypertension
No (N = 12) Yes (N = 30) p value No (N = 20) Yes (N = 22) p value
Qualitative variables
Sex (F:M) 11:1 28:2 n.s. 20:0 19:3 n.s.
Class of arterial involvement:
1
2A
2B
3
4
5
1
2
1
0
0
8
3
2
2
1
0
22
n.s.
n.s.
n.s.
n.s.
N.A.
n.s.
2
3
1
1
0
13
2
1
2
0
0
17
n.s.
n.s.
n.s.
n.s.
N.A.
n.s.
Aneurysms 6 10 n.s. 7 9 n.s.
Steroids 3 27 <0.001 13 17 n.s.
Immunosuppressive therapy: 7 23 n.s. 11 19 0.04
Biologic therapy:
TNF blockers
Tocilizumab
4
3
1
15
13
1
n.s.
n.s.
n.s.
10
9
1
9
7
1
n.s.
n.s.
n.s.
Active disease (NIH criteria) 0 12 0.009 5 6 n.s.
Anticoagulants 3 4 n.s. 3 4 n.s.
Arterial hypertension 4 18 n.s. N.E. N.E.
Therapy with PPIs N.E. N.E.
Cardiac involvement 4 8 n.s. 6 6 n.s.
Vascular enhancement (N = 30) 1 4 n.s. 3 2 n.s.
Vascular progression (N = 40) 1 8 n.s. 5 4 n.s.
Scalar variables (median and range)
Age (years) 51 (31–66) 41 (23–62) 0.060 40 (23–66) 47 (26–65) n.s.
Age at TA onset (years) 36 (21–56) 28 (17–56) n.s. 29 (17–56) 30 (18–56) n.s.
Disease duration (years) 12 (4–21) 9 (0–34) n.s. 9 (2–21) 11 (0–34) n.s.
Creatinine (mg/dl) 0.70 (0.44–1.06) 0.70 (0.56–1.60) n.s. 0.67 (0.49–0.89) 0.75 (0.44–1.61) 0.084
PDN dose (mg/day) 0 (0–12.5) 5 (0–35) <0.001 5 (0–25) 5 (0–35) n.s.
N vessels 4 (1–6) 4 (1–7) n.s. 3 (1–-6) 4 (1–7) n.s.
ESR (mm/h) 9 (1–23) 18 (2–78) 0.059 13 (2–73) 18 (1–78) n.s.
Serum CRP (mg/l) 1.5 (0.1–12) 3.0 (0.3–40) 0.104 2.0 (0.1-40) 2.6 (0.3–36.8) n.s.
Plasma PTX3 (ng/ml) 4.1 (1.3–44) 5.9 (2.2–55) n.s. 5.8 (2.5–43.6) 5.3 (1.3–55.0) n.s.
CgAtot (nM) 1.02 (0.45–2.66) 3.40 (0.60–7.85) <0.001 1.35 (0.5–3-6.31) 3.76 (0.45–7.85) 0.021
CgA439 (nM) 0 (0-0–19) 0.07 (0–0.78) n.s. 0.01 (0–0.44) 0.07 (0–0.78) n.s.
CgA-FRs (nM) 0.76 (0.22–1.82) 2.18 (0.28–6.68) <0.001 0.89 (0.39–3.93) 2.45 (0.22–6.68) 0.030
VS-1 (nM) 0.10 (0.02–0.34) 0.25 (0.06–1.15) 0.001 0.11 (0.02–0.79) 0.32 (0.05–1.15) 0.024
CgA439/CgAtot 0 % (0–18 %) 2 % (0–24 %) n.s. 0 % (0–18 %) 2 % (0–24 %) n.s.
CgA-FRs/CgAtot 69 % (50–84 %) 66 % (47–94 %) n.s. 69 % (50–84 %) 66 % (47–94 %) n.s.
VS-1/CgAtot 12 % (1–24 %) 10 % (3–27 %) n.s. 12 % (1–24 %) 10 % (3–27 %) n.s.
Rank CgA439+ rank VS-1 27 (5–50) 41 (18–83) 0.002 32 (5–64) 44 (8–83) 0.023
Quantitative and qualitative variables related to TA were evaluated, verifying the impact of the treatment with PPIs and of arterial hypertension. N vessels refers to
the number of vessels involved by the disease (see “Methods”)
TA Takayasu arteritis, PPI proton-pump inhibitor, n.s. not significant, N.A. not available, TNF tumour necrosis factor, N.E. not evaluable, PDN prednisone, ESR erythrocyte
sedimentation rate, CRP C-reactive protein, PTX3 pentraxin-3, CgAtot total chromogranin-A, CgA439 full-length CgA (residues 1–439), CgA-FRs fragments of CgA spanning
from the N-terminus to the central region but lacking the C-terminal region, VS-1 vasostatin-1
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immunosuppressive agents had higher CgA-FRs, and the
difference was maintained after stratification for PPIs
(Additional file 4: Table S3) or for arterial hypertension
(data not shown). Moreover, patients on immunosuppres-
sive therapy had lower CgA-FRs/CgAtot and a trend to-
wards lower VS-1/CgAtot (Additional file 4: Table S3),
suggesting specific regulation of CgA processing. Absolute
or relative concentrations of CgA and its peptides were
similar in patients with or without TNF blockers or anti-
coagulant therapies (data not shown).
Multivariate analysis
To verify the correlation between stratifying variables
and plasma levels of CgA peptides, we performed a four-
factor analysis of variance (ANOVA) (Additional file 5:
Table S2). Plasmatic levels of CgA peptides were related
Table 3 Correlations of the CgA peptides in TA patients with
markers of systemic and local inflammation and with the
number of involved vessels
Whole TA group (N = 42)
CgA439 CgA-FRs VS-1 CgAtot
ESR 0.179
n.s.
0.181
n.s.
0.173
n.s.
0.158
n.s.
CRP 0.015
n.s.
0.326
p = 0.035
0.229
n.s.
0.300
p = 0.053
PTX3 -0.232
n.s.
-0.082
n.s.
0.291
p = 0.062
0.085
n.s.
N vessels 0.196
n.s.
0.039
n.s.
-0.047
n.s.
0.066
n.s.
CgA439/CgAtot CgA-FRs/CgAtot VS-1/CgAtot
ESR 0.134
n.s.
0.178
n.s.
0.016
n.s.
CRP -0.009
n.s.
0.088
n.s.
-0.123
n.s.
PTX3 -0.022
n.s.
-0.123
n.s.
0.154
n.s.
N vessels 0.153
n.s.
-0.176
n.s.
-0.178
n.s.
TA on PPIs (N = 30)
CgA439 CgA-FRs VS-1 CgAtot
ESR 0.119
n.s.
0.045
n.s.
0.010
n.s.
0.002
n.s.
CRP 0.030
n.s.
0.140
n.s.
0.028
n.s.
0.142
n.s.
PTX3 -0.258
n.s.
0.065
n.s.
0.176
n.s.
0.071
n.s.
N vessels 0.309
p = 0.096
0.017
n.s.
-0.009
n.s.
0.076
n.s.
CgA439/CgAtot CgA-FRs/CgAtot VS-1/CgAtot
ESR 0.174
n.s.
0.319
p = 0.097
-0.009
n.s.
CRP 0.106
n.s.
0.200
n.s.
-0.169
n.s.
PTX3 -0.241
n.s.
0.037
n.s.
0.133
n.s.
N vessels 0.251
n.s.
-0.194
n.s.
-0.138
n.s.
Normotensive TA (N = 20)
CgA439 CgA-FRs VS-1 CgAtot
ESR -0.368
n.s.
-0.028
n.s.
0.415
p = 0.110
-0.162
n.s.
CRP -0.124
n.s.
0.389
p = 0.090
0.576
p = 0.008
0.346
n.s.
PTX3 -0.422
p = 0.061
0.030
n.s.
0.386
p = 0.093
-0.003
n.s.
N vessels -0.074
n.s.
0.088
n.s.
0.029
n.s.
0.082
n.s.
CgA439/CgAtot CgA-FRs/CgAtot VS-1/CgAtot
ESR -0.168
n.s.
0.570
p = 0.021
0.684
p = 0.003
Table 3 Correlations of the CgA peptides in TA patients with
markers of systemic and local inflammation and with the
number of involved vessels (Continued)
CRP -0.036
n.s.
0.254
n.s.
-0.309
n.s.
PTX3 -0.435
p = 0.055
0.159
n.s.
0.480
p = 0.032
N vessels 0.072
n.s.
-0.012
n.s.
-0.057
n.s.
Hypertensive TA (N = 22)
CgA439 CgA-FRs VS-1 CgAtot
ESR 0.517
p = 0.020
0.295
n.s.
-0.192
n.s.
0.276
n.s.
CRP 0.149
n.s.
0.347
n.s.
0.049
n.s.
0.324
n.s.
PTX3 -0.030
n.s.
0.157
n.s.
0.088
n.s.
0.153
n.s.
N vessels 0.382
p = 0.076
-0.222
n.s.
-0.259
n.s.
-0.104
n.s.
CgA439/CgAtot CgA-FRs/CgAtot VS-1/CgAtot
ESR 0.536
p = 0.015
-0.085
n.s.
-0.561
p = 0.010
CRP 0.134
n.s.
0.136
n.s.
-0.455
p = 0.033
PTX3 -0.052
n.s.
-0.082
n.s.
-0.010
n.s.
N vessels 0.389
p = 0.073
-0.203
n.s.
-0.311
n.s.
Levels of CgA439, CgA-FRs, VS-1 or their ratios to CgAtot were correlated with
markers of systemic inflammation (ESR and CRP), of local inflammation (PTX3)
and with the number of vessels involved by the disease (N vessels, see
“Methods”). The impact of the treatment with PPIs and of arterial hypertension
is also considered. The Spearman correlation coefficient and the relative p
values are shown
CgA chromogranin-A, TA Takayasu arteritis, CgA439 full-length CgA (residues 1–439),
CgA-FRs fragments of CgA spanning from the N-terminus to the central region but
lacking the C-terminal region, VS-1 vasostatin-1, CgAtot total CgA, ESR erythrocyte
sedimentation rate, n.s. not significant, CRP C-reactive protein, PTX3 pentraxin-3,
PPI proton-pump inhibitor
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Fig. 2 (See legend on next page.)
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with therapy with PPI, and the VS-1/CgAtotratio with
treatment with immunosuppressive agents. The relation-
ship between the presence of arterial hypertension and
the plasma levels of CgA-FR and VS-1 did not reach the
threshold set for statistical significance (p = 0.117 and
0.087, respectively), possibly because of the number of
factors relatively to the sample size and of the association
between arterial hypertension and therapy with immuno-
suppressive agents (p = 0.040, Table 2). Importantly, arter-
ial progression correlated with reduced anti-angiogenic
CgA potential (p = 0.032) at the four-way ANOVA analysis
(Additional file 5: Table S2).
Discussion
We make some significant observations. First, total CgA
and many bioactive CgA-derived peptides are increased
in TA patients. Second, inter-patient variability indicates
that the CgA system is modulated in TA. Correlation
studies show that variables related to disease phenotype
(e.g. arterial hypertension), anti-rheumatic drugs and
other supportive medications (e.g. PPIs) influence the
CgA system and impact on its relationship with inflam-
mation. CgA-derived peptides have been proved to be
biologically active in vivo and to influence vascular
events involved in the pathogenesis of TA and we ob-
served a reduced anti-angiogenic CgA potential in pa-
tients undergoing vascular progression. The resulting
effect of pro- and anti-angiogenic CgA forms is difficult
to predict in TA patients, and further studies are needed
to confirm these preliminary observations. However, our
findings raise the possibility that therapies commonly
used in patients with vasculitis may indirectly influence
vascular events by modulating the CgA system.
Vasa vasorum neongiogenesis is typical of large vessel
vasculitides [11, 12]. Inflammatory cells infiltrate vascu-
litic lesions through vasa vasorum, and neoangiogenesis
within arterial lesions have been associated with histo-
logic features, such as disruption of the internal elastic
membrane and intimal hyperplasia, which is thought to
cause stenosis [11, 30]. The CgA system modulates
neoangiogenesis [15, 17] and fibroblast adhesion, endo-
thelial and VSMC proliferation and migration, and endo-
thelial response to inflammatory stimuli.
PPIs raise CgA levels by inducing gastric entherochro-
maffin cell hyperplasia as a consequence of hypochlorhy-
dia. We found that patients treated with PPIs had
increased levels of CgA-FRs and VS-1, even if the CgA
processing is apparently conserved. PPI treatment is
common in TA because of the use of steroids, anticoag-
ulants and/or anti-platelet agents. Our data raise the
possibility that PPIs indirectly influence vascular events
in TA via the CgA system. It is difficult to predict
whether the final effect of PPIs would be vaso-protective
or not, because different CgA-derived peptides have op-
posite actions with non-linear concentration-response
curves [15, 17]. Over-prescription of acid secretion-
blocking therapies is frequent, and we suggest limiting
these agents to TA patients with a clear indication or
using other gastro-protective agents until further pro-
spective studies on larger cohorts clarify effects of PPIs
on vascular biology. In this regard, TA would represent a
paradigmatic condition, as poorly known effects of com-
mon medications are likely to occur also in other dis-
eases. Therapy with non-biologic immunosuppressive
agents was associated with regulation of the CgA system
and an altered processing of CgA. It would be important
to understand the mechanisms of this effect and whether
this may be helpful or detrimental in large vessel
vasculitis.
We found that arterial hypertension was associated
with higher levels of CgA-FR and VS-1 in TA, and that
a normotensive or hypertensive status influenced the
link between the CgA system and inflammation in TA.
Arterial hypertension has a complex relationship with
the CgA system, as hypertensive patients have higher
levels of total CgA [31], but deletion of the CgA gene
causes development of arterial hypertension in mice
[32]. Higher adrenergic tone and CgA release in hyper-
tensive patients, together with a negative feedback of
CgA-derived peptides (such as catestatin on sympathetic
terminals), are believed to explain such findings [33, 34].
In TA, concurrent inflammation and vascular injury
adds another level of complexity. Arterial hypertension
is frequent in TA and identifies patients with a worse
outcome [7]. Specific disease-related mechanisms are
supposed to participate in arterial hypertension in these
patients [6]: renal hypoperfusion due to renal artery
stenosis or atypical aortic coarctation, reduction of total
arterial compliance due to widespread arterial involve-
ment, baroreceptor dysfunction due to aortic arch or
supra-aortic involvement, and steroid side effects. In this
context, our data suggest a potential multi-directional
interference between arterial hypertension, inflammation
and vascular involvement.
(See figure on previous page.)
Fig. 2 Levels of CgA peptides and selected TA clinical features. Plasma concentrations of CgA439, CgA-FRs and VS-1 in the whole group of TA
patients (left panels) and in those on PPI therapy (right panels), stratified for vascular enhancement (upper panels), disease activity (middle panels)
and vascular progression (lower panels) (see “Methods”). CgA439 full-length chromogranin-A (residues 1–439), CgA-FRs fragments of CgA spanning
from the N-terminus to the central region but lacking the C-terminal region, PPI proton-pump inhibitors, VS-1 vasostatin-1
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Table 4 CgA peptides according to the presence of arterial wall enhancement, of active TA and of vascular progression
Whole TA sample No arterial wall enhancement (N = 25) Arterial wall enhancement (N = 5) p value
CgA439 (nM) 0.06 (0–0.62) 0.00 (0–0.78) n.s.
CgA-FRs (nM) 1.85 (0.39–5.03) 1.41 (0.32–3.93) n.s.
VS-1 (nM) 0.25 (0.02–1.15) 0.23 (0.10–0.79) n.s.
Rank CgA439 + rank VS-1 38 (5–83) 36 (24–80) n.s.
Patients on PPIs No arterial wall enhancement (N = 20) Arterial wall enhancement (N = 4) p value
CgA439 (nM) 0.07 (0–0.62) 0.00 (0–0.78) n.s.
CgA-FRs (nM) 2.45 (0.41–5.03) 2.60 (1.25–3.93) n.s.
VS-1 (nM) 0.27 (0.06-1.15) 0.48 (0.22–0.79) n.s.
Rank CgA439 + rank VS-1 44 (29–83) 32 (24–80) n.s.
Hypertensive patients No arterial wall enhancement (N = 13) Arterial wall enhancement (N = 2) p value
CgA439 (nM) 0.06 (0–0.62) 0.43 (0.09–0.78) n.s.
CgA-FRs (nM) 2.76 (0.77–5.03) 2.06 (0.32–3.8) n.s.
VS-1 (nM) 0.38 (0.17–1.15) 0.42 (0.10–0.74) n.s.
Rank CgA439 + rank VS-1 50 (28–83) 58 (36–80) n.s.
Whole TA sample Inactive TA (N = 30) Active TA (N = 12) p value
CgA439 (nM) 0.05 (0–0.62) 0.03 (0–0.78) n.s.
CgA-FRs (nM) 1.37 (0.22–6.68) 1.80 (0.28–5.03) n.s.
VS-1 (nM) 0.19 (0.02–1.15) 0.21 (0.09–0.79) n.s.
Rank CgA439 + rank VS-1 37 (5–83) 35 (18–80) n.s.
Patients on PPIs Inactive TA (N = 18) Active TA (N = 12) p value
CgA439 (nM) 0.08 (0–0.62) 0.03 (0–0.78) n.s.
CgA-FRs (nM) 2.55 (0.41–6.68) 1.80 (0.28–5.03) n.s.
VS-1 (nM) 0.32 (0.06–1.15) 0.21 (0.09–0.79) n.s.
Rank CgA439 + rank VS-1 52 (24–83) 35 (18–80) 0.072
Hypertensive patients Inactive TA (N = 15) Active TA (N = 7) p value
CgA439 (nM) 0.08 (0–0.62) 0.06 (0–0.78) n.s.
CgA-FRs (nM) 2.50 (0.22–6.68) 1.85 (0.28–5.03) n.s.
VS-1 (nM) 0.39 (0.05–1.15) 0.20 (0.09–0.74) n.s.
Rank CgA439 + rank VS-1 50 (8–83) 39 (18–80) n.s.
Whole TA sample No vascular progression (N = 31) Vascular progression (N = 9) p value
CgA439 (nM) 0.06 (0–0.78) 0 (0–0.14) n.s.
CgA-FRs (nM) 1.49 (0.22–5.03) 1.76 (0.32–4.24) n.s.
VS-1 (nM) 0.20 (0.02–1.15) 0.20 (0.09–0.79) n.s.
Rank CgA439+ rank VS-1 42 (5–83) 36 (22–40) n.s.
Patients on PPIs No vascular progression (N = 20) Vascular progression (N = 8) p value
CgA439 (nM) 0.09 (0–0.78) 0 (0–0.14) 0.063
CgA-FRs (nM) 2.45 (0.41–5.03) 1.81 (0.46–4.24) n.s.
VS-1 (nM) 0.27 (0.06–1.15) 0.21 (0.09–0.79) n.s.
Rank CgA439 + rank VS-1 52 (24–83) 34.5 (22–40) 0.010
Hypertensive patients No vascular progression (N = 16) Vascular progression (N = 4) p value
CgA439 (nM) 0.08 (0–0.78) 0.05 (0–0.14) n.s.
CgA-FRs (nM) 2.63 (0.22–5.03) 1.40 (0.32–4.24) n.s.
VS-1 (nM) 0.39 (0.05–1.15) 0.15 (0.09–0.37) n.s.
Rank CgA439 + rank VS-1 52 (8–83) 33 (22–39) 0.050
Levels of CgA439, CgA-FRS, VS-1 and the sum of the ranks of CgA439 and of VS-1 are compared according to the presence of arterial wall enhancement, of active
disease and of vascular progression. The impact of PPI therapy or arterial hypertension is also considered
CgA chromogranin-A, TA Takayasu arteritis, CgA439 full-length CgA (residues 1–439), n.s. not significant, CgA-FRs fragments of CgA spanning from the N-terminus to
the central region but lacking the C-terminal region, VS-1 vasostatin-1, PPI proton-pump inhibitor
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This study has limitations: first, we used imaging and
pentraxin-3 rather than histology for assessing vascular
inflammation, since surgery is rarely performed in TA.
Second, TA is a rare disease and large cohorts are diffi-
cult to establish. This is an observational study and the
relatively small number of patients and the confounding
effects of disease- and treatment-associated variables
might limit its statistical power. Despite these limita-
tions, a statistically significant inverse association has
been detected between the levels of anti-angiogenic CgA
peptides and vascular progression in the more active TA
patients on PPI. A similar inverse association has been
detected in TA patients with arterial hypertension. These
results might reflect a protective action of signals limit-
ing angiogenesis associated to the arterial wall, which
could as well restrict the maladaptive vascular remodel-
ling that is the hallmark of TA. Further prospective stud-
ies on larger groups of patients are warranted to verify
whether this is indeed the case.
Conclusions
We observed marked alterations in TA of the circulating
levels of CgA-derived polypeptides that might have an
effect on the vascular biology. Both disease- and
therapy-related variables influence the blood levels of
CgA-derived peptides. Until further study clarifies the
potential role of CgA-derived polypeptides in large ves-
sel vasculitis, care should be taken with correct prescrip-
tion of anti-rheumatic and supportive medications, such
as PPIs.
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